These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 34380180)

  • 1. A fast screening method for the detection of CERA in dried blood spots.
    Rocca A; Martin L; Kuuranne T; Ericsson M; Marchand A; Leuenberger N
    Drug Test Anal; 2022 May; 14(5):820-825. PubMed ID: 34380180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of erythropoiesis-stimulating agents in a single dried blood spot.
    Reverter-Branchat G; Ventura R; Ezzel Din M; Mateus J; Pedro C; Segura J
    Drug Test Anal; 2018 Oct; 10(10):1496-1507. PubMed ID: 29877055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimizing detection of erythropoietin receptor agonists from dried blood spots for anti-doping application.
    Heiland CE; Ericsson M; Pohanka A; Ekström L; Marchand A
    Drug Test Anal; 2022 Aug; 14(8):1377-1386. PubMed ID: 35322582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A rapid and simple assay to determine pegylated erythropoietin in human serum.
    Van Maerken T; Dhondt A; Delanghe JR
    J Appl Physiol (1985); 2010 Apr; 108(4):800-3. PubMed ID: 20093664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Confirmatory analysis of continuous erythropoietin receptor activator and erythropoietin analogues in equine plasma by LC-MS for doping control.
    Guan F; Uboh CE; Soma LR; Maylin G; Jiang Z; Chen J
    Anal Chem; 2010 Nov; 82(21):9074-81. PubMed ID: 20945883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liquid chromatography - high resolution mass spectrometry-based metabolomic approach for the detection of Continuous Erythropoiesis Receptor Activator effects in horse doping control.
    Joré C; Loup B; Garcia P; Paris AC; Popot MA; Audran M; Bonnaire Y; Varlet-Marie E; Bailly-Chouriberry L
    J Chromatogr A; 2017 Oct; 1521():90-99. PubMed ID: 28941809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of single doses of methoxypolyethylene glycol-epoetin beta (CERA, Mircera™) and epoetin delta (Dynepo™) on isoelectric erythropoietin profiles and haematological parameters.
    Dehnes Y; Hemmersbach P
    Drug Test Anal; 2011 May; 3(5):291-9. PubMed ID: 21387570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hemoglobin maintenance and dosing strategies using intravenous continuous erythropoietin receptor activator in Japanese hemodialysis patients.
    Hirai T; Nishizawa Y; Nakazono H; Asai M; Yamashita H; Sasaki A; Yamashita T; Yamashita K; Shigemoto K; Harada S; Mizuiri S
    Ther Apher Dial; 2013 Oct; 17(5):498-503. PubMed ID: 24107278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful Treatment of Antibody-mediated Pure Red Cell Aplasia Induced by Continuous Erythropoietin Receptor Activator with Prednisolone.
    Okahashi N; Kubo M; Hoshino E; Uchihara M; Amano I; Tanaka H
    Intern Med; 2022 Jul; 61(14):2209-2213. PubMed ID: 34980800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Opatija study: observation of hemodialysis patients and titration of CERA dose just switched from another erythropoiesis stimulating agent].
    Jelić I; Lovcić V; Kurtović I; Josipović M; Havranek Z; Kostić L; Racki S
    Acta Med Croatica; 2012 Jul; 66(3):157-64. PubMed ID: 23441529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early responsiveness to continuous erythropoietin receptor activator predicts renal prognosis and is determined by a novel antioxidative marker in non-dialysis chronic kidney disease: a prospective, observational, single-center study.
    Ino J; Kasama E; Kodama M; Harada T; Sato K; Eizumi H; Kawashima Y; Nitta K
    Clin Exp Nephrol; 2020 Jul; 24(7):590-597. PubMed ID: 32185544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of pain and efficacy of darbepoetin alfa and epoetin Beta pegol treatment in patients receiving peritoneal dialysis.
    Otsuka T; Sakai Y; Yui S; Sukegawa M; Suzuki A; Mugishima K; Sumi Y; Otsuka Y; Tsuruoka S
    J Nippon Med Sch; 2015; 82(1):21-6. PubMed ID: 25797871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A simple method to immunopurify erthyropoiesis stimulating agents from urine, aiming to optimize erythropoietin screening by SAR-PAGE.
    Heiland CE; Masquelier M; Bhuiyan H; Ericsson M
    Drug Test Anal; 2019 Nov; 11(11-12):1666-1674. PubMed ID: 31692286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Switching From Darbepoetin Alfa to Epoetin Beta Pegol on Iron Utilization and Blood Pressure in Peritoneal Dialysis Patients.
    Washida N; Inoue S; Kasai T; Shinozuka K; Hosoya K; Morimoto K; Wakino S; Hayashi K; Itoh H
    Ther Apher Dial; 2015 Oct; 19(5):450-6. PubMed ID: 25944557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Report on an anti-doping operation in Guadeloupe: High number of positive cases and inferences about doping habits.
    Marchand A; Buisson C; Martin L; Martin JA; Molina A; Ressiot D
    Drug Test Anal; 2017 Nov; 9(11-12):1753-1761. PubMed ID: 28296276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of Stimulated Erythropoiesis by the RNA-Based 5'-Aminolevulinate Synthase 2 Biomarker in Dried Blood Spot Samples.
    Salamin O; Gottardo E; Schobinger C; Reverter-Branchat G; Segura J; Saugy M; Kuuranne T; Tissot JD; Favrat B; Leuenberger N
    Clin Chem; 2019 Dec; 65(12):1563-1571. PubMed ID: 31570629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparing the efficacy of continuous erythropoietin receptor activator and darbepoetin Alfa treatments in Japanese patients with chronic kidney disease during the predialysis period: A propensity-matched analysis.
    Koibuchi K; Miyagi M; Arai T; Aoki T; Aikawa A; Sakai K
    Nephrology (Carlton); 2015 Dec; 20 Suppl 4():22-8. PubMed ID: 26456234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of a simple dosage scheme to convert from shorter-acting erythropoiesis-stimulating agent to continuous erythropoietin receptor activator in kidney transplantation patients.
    Sánchez-Escuredo A; Batista F; Cases A; Torregrosa JV
    Transplant Proc; 2015; 47(1):73-5. PubMed ID: 25645774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How to confirm C.E.R.A. doping in athletes' blood?
    Leuenberger N; Lamon S; Robinson N; Giraud S; Saugy M
    Forensic Sci Int; 2011 Dec; 213(1-3):101-3. PubMed ID: 21889277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Time spent on erythropoietin stimulating agents administration in hemodialysis centers in Panama: a time and motion study.
    Chacón-Araya M; Rey-Rodríguez D; Rodríguez De León F; Ramos-Esquivel A; Sunning T
    J Med Econ; 2019 Aug; 22(8):736-741. PubMed ID: 30915883
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.